Use of a web-based app to improve breast cancer symptom management and adherence for aromatase inhibitors

a randomized controlled feasibility trial

Ilana Yonas, Caitlin N. McKillop, Edward Stepanski, Gregory Vidal, Janeane N. Anderson, Lee Schwartzberg

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose: For postmenopausal women with hormone receptor-positive breast cancer, long-term use of aromatase inhibitors (AIs) significantly reduces the risk of cancer recurrence and improves survival. Still, many patients are nonadherent due to adverse side effects. We conducted a pilot randomized controlled trial to test the use of a web-based application (app) designed with and without weekly reminders for patients to report real-time symptoms and AI use outside of clinic visits with built-in alerts to patients’ oncology providers. Our goal was to improve symptom burden and medication adherence. Methods: Forty-four women with early-stage breast cancer and a new AI prescription were randomized to either an App+Reminder (weekly reminders to use app) or an App (no reminders) group. Pre- and post-assessment data were collected from all participants. Results: Participants in the App+Reminder group had higher weekly app usage rate (74 vs. 38%, p < 0.05) during the intervention and reported higher AI adherence at 8 weeks (100 vs. 72%, p < 0.05). Symptom burden increase was higher for the App group compared to the App+Reminder group but did not reach statistical significance. Conclusions: Weekly reminders to use a web-based app to report AI adherence and treatment-related symptoms demonstrated feasibility and improved short-term AI adherence, which may reduce symptom burden for women with breast cancer and a new AI prescription. Implications for Cancer Survivors: If short-term gains in adherence persist, this low-cost intervention could improve survival outcomes for women with breast cancer. A larger, long-term study should examine if AI adherence and symptom burden improvements persist for a 5-year treatment period.

Original languageEnglish (US)
Pages (from-to)431-440
Number of pages10
JournalJournal of Cancer Survivorship
Volume12
Issue number4
DOIs
StatePublished - Aug 1 2018

Fingerprint

Aromatase Inhibitors
Randomized Controlled Trials
Breast Neoplasms
Prescriptions
Survival
Medication Adherence
Ambulatory Care
Survivors
Neoplasms
Hormones
Costs and Cost Analysis
Recurrence
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Oncology(nursing)

Cite this

Use of a web-based app to improve breast cancer symptom management and adherence for aromatase inhibitors : a randomized controlled feasibility trial. / Yonas, Ilana; McKillop, Caitlin N.; Stepanski, Edward; Vidal, Gregory; Anderson, Janeane N.; Schwartzberg, Lee.

In: Journal of Cancer Survivorship, Vol. 12, No. 4, 01.08.2018, p. 431-440.

Research output: Contribution to journalArticle

@article{a400e3ffad124ad1a049eeb258bdce4b,
title = "Use of a web-based app to improve breast cancer symptom management and adherence for aromatase inhibitors: a randomized controlled feasibility trial",
abstract = "Purpose: For postmenopausal women with hormone receptor-positive breast cancer, long-term use of aromatase inhibitors (AIs) significantly reduces the risk of cancer recurrence and improves survival. Still, many patients are nonadherent due to adverse side effects. We conducted a pilot randomized controlled trial to test the use of a web-based application (app) designed with and without weekly reminders for patients to report real-time symptoms and AI use outside of clinic visits with built-in alerts to patients’ oncology providers. Our goal was to improve symptom burden and medication adherence. Methods: Forty-four women with early-stage breast cancer and a new AI prescription were randomized to either an App+Reminder (weekly reminders to use app) or an App (no reminders) group. Pre- and post-assessment data were collected from all participants. Results: Participants in the App+Reminder group had higher weekly app usage rate (74 vs. 38{\%}, p < 0.05) during the intervention and reported higher AI adherence at 8 weeks (100 vs. 72{\%}, p < 0.05). Symptom burden increase was higher for the App group compared to the App+Reminder group but did not reach statistical significance. Conclusions: Weekly reminders to use a web-based app to report AI adherence and treatment-related symptoms demonstrated feasibility and improved short-term AI adherence, which may reduce symptom burden for women with breast cancer and a new AI prescription. Implications for Cancer Survivors: If short-term gains in adherence persist, this low-cost intervention could improve survival outcomes for women with breast cancer. A larger, long-term study should examine if AI adherence and symptom burden improvements persist for a 5-year treatment period.",
author = "Ilana Yonas and McKillop, {Caitlin N.} and Edward Stepanski and Gregory Vidal and Anderson, {Janeane N.} and Lee Schwartzberg",
year = "2018",
month = "8",
day = "1",
doi = "10.1007/s11764-018-0682-z",
language = "English (US)",
volume = "12",
pages = "431--440",
journal = "Journal of Cancer Survivorship",
issn = "1932-2259",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Use of a web-based app to improve breast cancer symptom management and adherence for aromatase inhibitors

T2 - a randomized controlled feasibility trial

AU - Yonas, Ilana

AU - McKillop, Caitlin N.

AU - Stepanski, Edward

AU - Vidal, Gregory

AU - Anderson, Janeane N.

AU - Schwartzberg, Lee

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Purpose: For postmenopausal women with hormone receptor-positive breast cancer, long-term use of aromatase inhibitors (AIs) significantly reduces the risk of cancer recurrence and improves survival. Still, many patients are nonadherent due to adverse side effects. We conducted a pilot randomized controlled trial to test the use of a web-based application (app) designed with and without weekly reminders for patients to report real-time symptoms and AI use outside of clinic visits with built-in alerts to patients’ oncology providers. Our goal was to improve symptom burden and medication adherence. Methods: Forty-four women with early-stage breast cancer and a new AI prescription were randomized to either an App+Reminder (weekly reminders to use app) or an App (no reminders) group. Pre- and post-assessment data were collected from all participants. Results: Participants in the App+Reminder group had higher weekly app usage rate (74 vs. 38%, p < 0.05) during the intervention and reported higher AI adherence at 8 weeks (100 vs. 72%, p < 0.05). Symptom burden increase was higher for the App group compared to the App+Reminder group but did not reach statistical significance. Conclusions: Weekly reminders to use a web-based app to report AI adherence and treatment-related symptoms demonstrated feasibility and improved short-term AI adherence, which may reduce symptom burden for women with breast cancer and a new AI prescription. Implications for Cancer Survivors: If short-term gains in adherence persist, this low-cost intervention could improve survival outcomes for women with breast cancer. A larger, long-term study should examine if AI adherence and symptom burden improvements persist for a 5-year treatment period.

AB - Purpose: For postmenopausal women with hormone receptor-positive breast cancer, long-term use of aromatase inhibitors (AIs) significantly reduces the risk of cancer recurrence and improves survival. Still, many patients are nonadherent due to adverse side effects. We conducted a pilot randomized controlled trial to test the use of a web-based application (app) designed with and without weekly reminders for patients to report real-time symptoms and AI use outside of clinic visits with built-in alerts to patients’ oncology providers. Our goal was to improve symptom burden and medication adherence. Methods: Forty-four women with early-stage breast cancer and a new AI prescription were randomized to either an App+Reminder (weekly reminders to use app) or an App (no reminders) group. Pre- and post-assessment data were collected from all participants. Results: Participants in the App+Reminder group had higher weekly app usage rate (74 vs. 38%, p < 0.05) during the intervention and reported higher AI adherence at 8 weeks (100 vs. 72%, p < 0.05). Symptom burden increase was higher for the App group compared to the App+Reminder group but did not reach statistical significance. Conclusions: Weekly reminders to use a web-based app to report AI adherence and treatment-related symptoms demonstrated feasibility and improved short-term AI adherence, which may reduce symptom burden for women with breast cancer and a new AI prescription. Implications for Cancer Survivors: If short-term gains in adherence persist, this low-cost intervention could improve survival outcomes for women with breast cancer. A larger, long-term study should examine if AI adherence and symptom burden improvements persist for a 5-year treatment period.

UR - http://www.scopus.com/inward/record.url?scp=85042603538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042603538&partnerID=8YFLogxK

U2 - 10.1007/s11764-018-0682-z

DO - 10.1007/s11764-018-0682-z

M3 - Article

VL - 12

SP - 431

EP - 440

JO - Journal of Cancer Survivorship

JF - Journal of Cancer Survivorship

SN - 1932-2259

IS - 4

ER -